BACKGROUND: Increasing numbers of children with advanced neuroblastoma are achieving cure. We describe the clinical late effects specific to survivors of stage IV neuroblastoma all similarly treated using tandem autologous peripheral blood stem cell rescue with TBI. METHOD: The medical records of 35 neuroblastoma patients treated at CHOP between 1997 and 2001 were examined. Eighteen of the 35 patients died of progressive disease, and 4 were lost to follow-up. Thirteen patients continue to follow-up in our Multidisciplinary Cancer Survivorship Clinic where they are evaluated and monitored by a consistent group of subspecialists that evaluate long-term sequelae. Data on treatment exposures including TBI and treatment related sequelae identified by clinician assessment and/or diagnostic testing were collected. RESULTS: Results indicate late effects were present in all 13 subjects, 12 of whom suffered from multiple negative sequelae, including issues with growth hormone deficiency, dental problems, osteochondromas and hearing deficiencies, among others, most at higher rates than reported previously. CONCLUSIONS: The findings in this small cohort indicate the need for future prospective studies of this intensive pediatric cancer treatment, and underscore the importance of medical intervention and long-term monitoring of these at-risk subjects to increase overall quality-of-life. (c) 2008 Wiley-Liss, Inc.
BACKGROUND: Increasing numbers of children with advanced neuroblastoma are achieving cure. We describe the clinical late effects specific to survivors of stage IV neuroblastoma all similarly treated using tandem autologous peripheral blood stem cell rescue with TBI. METHOD: The medical records of 35 neuroblastomapatients treated at CHOP between 1997 and 2001 were examined. Eighteen of the 35 patients died of progressive disease, and 4 were lost to follow-up. Thirteen patients continue to follow-up in our Multidisciplinary Cancer Survivorship Clinic where they are evaluated and monitored by a consistent group of subspecialists that evaluate long-term sequelae. Data on treatment exposures including TBI and treatment related sequelae identified by clinician assessment and/or diagnostic testing were collected. RESULTS: Results indicate late effects were present in all 13 subjects, 12 of whom suffered from multiple negative sequelae, including issues with growth hormone deficiency, dental problems, osteochondromas and hearing deficiencies, among others, most at higher rates than reported previously. CONCLUSIONS: The findings in this small cohort indicate the need for future prospective studies of this intensive pediatric cancer treatment, and underscore the importance of medical intervention and long-term monitoring of these at-risk subjects to increase overall quality-of-life. (c) 2008 Wiley-Liss, Inc.
Authors: S A Grupp; J W Stern; N Bunin; C Nancarrow; A A Ross; M Mogul; R Adams; H E Grier; J B Gorlin; R Shamberger; K Marcus; D Neuberg; H J Weinstein; L Diller Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: James G Gurney; Jean M Tersak; Kirsten K Ness; Wendy Landier; Katherine K Matthay; Mary Lou Schmidt Journal: Pediatrics Date: 2007-11 Impact factor: 7.124
Authors: Scott C Bresler; Andrew C Wood; Elizabeth A Haglund; Joshua Courtright; Lili T Belcastro; Jefferson S Plegaria; Kristina Cole; Yana Toporovskaya; Huaqing Zhao; Erica L Carpenter; James G Christensen; John M Maris; Mark A Lemmon; Yaël P Mossé Journal: Sci Transl Med Date: 2011-11-09 Impact factor: 17.956
Authors: E L Carpenter; E A Haglund; E M Mace; D Deng; D Martinez; A C Wood; A K Chow; D A Weiser; L T Belcastro; C Winter; S C Bresler; M Vigny; P Mazot; S Asgharzadeh; R C Seeger; H Zhao; R Guo; J G Christensen; J S Orange; B R Pawel; M A Lemmon; Y P Mossé Journal: Oncogene Date: 2012-01-23 Impact factor: 9.867
Authors: Brian H Kushner; Stephen S Roberts; Danielle N Friedman; Deborah Kuk; Irina Ostrovnaya; Shakeel Modak; Kim Kramer; Ellen M Basu; Nai-Kong V Cheung Journal: Cancer Date: 2015-02-27 Impact factor: 6.860
Authors: Carmen L Wilson; Tara M Brinkman; Cathleen Cook; Sujuan Huang; Geehong Hyun; Daniel M Green; Wayne L Furman; Nickhill Bhakta; Matthew J Ehrhardt; Matthew J Krasin; Leslie L Robison; Kirsten K Ness; Melissa M Hudson Journal: Cancer Date: 2020-01-10 Impact factor: 6.860
Authors: Ki Woong Sung; Hyo Seop Ahn; Bin Cho; Yong-Mook Choi; Nack Gyun Chung; Tai Ju Hwang; Ho Joon Im; Dae Chul Jeong; Hyoung Jin Kang; Hong Hoe Koo; Hoon Kook; Hack Ki Kim; Chuhl Joo Lyu; Jong Jin Seo; Hee Young Shin; Keon Hee Yoo; Sung Chul Won; Kun Soo Lee Journal: J Korean Med Sci Date: 2010-04-21 Impact factor: 2.153
Authors: Wendy Landier; Kristin Knight; F Lennie Wong; Jin Lee; Ola Thomas; Heeyoung Kim; Susan G Kreissman; Mary Lou Schmidt; Lu Chen; Wendy B London; James G Gurney; Smita Bhatia Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: L E Cohen; J H Gordon; E Y Popovsky; S Gunawardene; E Duffey-Lind; L E Lehmann; L R Diller Journal: Bone Marrow Transplant Date: 2014-01-20 Impact factor: 5.483
Authors: Ferro Nguyen; Ivan Alferiev; Peng Guan; David T Guerrero; Venkatadri Kolla; Ganesh S Moorthy; Michael Chorny; Garrett M Brodeur Journal: Clin Cancer Res Date: 2018-03-07 Impact factor: 12.531
Authors: Jorge Delgado; Diego Jaramillo; Nancy A Chauvin; Michelle Guo; Mackenzie S Stratton; Hannah E Sweeney; Christian A Barrera; Sogol Mostoufi-Moab Journal: Pediatr Radiol Date: 2019-05-04
Authors: Stephan A Grupp; Eline Luning Prak; Jean Boyer; Kenyetta R McDonald; Suzanne Shusterman; Edward Thompson; Colleen Callahan; Abbas F Jawad; Bruce L Levine; Carl H June; Kathleen E Sullivan Journal: Clin Cancer Res Date: 2012-10-23 Impact factor: 12.531